MyD88与乳腺癌新辅助化疗疗效的关系研究

发布时间：2018-03-22 11:00

  本文选题：乳腺癌　切入点：MyD88　出处：《广西医科大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的：髓样分化因子88(myeloid differentiation factor-88,MyD88)与肿瘤的发生、发展和耐药等事件密切相关。本文拟检测乳腺癌组织中MyD88的表达,初步探讨MyD88在乳腺癌化疗疗效预测中的潜在作用。方法：选择重庆市肿瘤医院2009.6-2013.6期间收治的乳腺浸润性导管癌患者59例,全部经病理组织学确诊、接受了4周期的TAC方案新辅助化疗；记录Topo Ⅱ、MDR 1、GST-π和p53的表达状况；应用免疫组织化学法检测MyD88在乳腺癌组织的表达；采用病理组织学、临床疗效和病理缓解(pCR)的标准评估新辅助化疗的疗效；分析MyD88表达与化疗疗效的关系,以及MyD88表达与Topo Ⅱ、MDR1、GST-π和p53基因表达的关系。结果：MyD88表达于部分乳腺癌患者,阳性表达率47.46%；其表达状况与乳腺癌化疗后的组织病理学反应相关(P=0.045),MyD88阳性表达者比阴性表达者疗效差；MyD88的表达状况与葸环类耐药相关的两个基因的表达相关,乳腺癌组织Topo Ⅱ(P=0.007)和p53(P=0.041)基因表达相关,提示MyD88可能与药物耐药有关。结论：MyD88在部分乳腺癌患者中呈阳性表达；MyD88的表达状况对乳腺癌TAC方案新辅助化疗的疗效具有潜在的预测价值；MyD88可能与TAC方案中的化疗药物耐药相关。
[Abstract]:Objective: myeloid differentiation factor 88(myeloid differentiation factor-88 MyD88 is closely related to the occurrence, development and drug resistance of tumor. This study is intended to detect the expression of MyD88 in breast cancer. To explore the potential role of MyD88 in predicting the curative effect of breast cancer chemotherapy. Methods: 59 patients with invasive ductal carcinoma of breast admitted in Chongqing Cancer Hospital from September to June 2013.6 were selected and confirmed by histopathology. Four cycles of neoadjuvant chemotherapy with TAC regimen were performed; the expression of GST- 蟺 and p53 in Topo 鈪，

本文编号：1648355